Learn how you can manage and alleviate your current side effects while actively working to prevent a relapse or secondary cancer using evidence-based, non-toxic therapies.
Click the orange button to the right to learn more.
Evidence-based research coupled with actionable therapy information. I launched PeopleBeatingCancer in ’04 thinking that I would do the above for cancer patients. However my research into therapies such as
have shown that I can provide both evidence-based research (see below) and actionable therapy information to people who suffer from chronic diseases such as ulcerative colitis (UC) as well.
For the record I’m not trying to offer an either/or, conventional/non-conventional proposition. I am offering research into integrative or complimentary therapies not discussed in your primary care physician’s office.
I take a broad spectrum probiotic supplement. Specific strains of probiotics benefit specific health issues. The study below supports VSL#3 High Potency Probiotic Capsules putting active ulcerative colitis patients into remission.
For more information about integrative therapies that may support UC patients, scroll down the page, post a question or comment and I will reply ASAP.
“BACKGROUND AND AIMS: Intestinal bacteria have been implicated in the initiation and perpetuation of IBD; in contrast, “probiotic bacteria” have properties possibly effective in treating and preventing relapse of IBD. We evaluated the safety and efficacy of VSL#3 and the components, and the composition of the biopsy-associated microbiota in patients with active mild to moderate ulcerative colitis (UC)…
Conclusion: Treatment of patients with mild to moderate UC, not responding to conventional therapy, with VSL#3 resulted in a combined induction of remission/response rate of 77% with no adverse events. At least some of the bacterial species incorporated in the probiotic product reached the target site in amounts that could be detected.”
“VSL#3 (VSL#3) is a high-concentration probiotic preparation of eight live freeze-dried bacterial species that are normal components of the human gastrointestinal microflora, including four strains of lactobacilli (Lactobacillus casei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), three strains of bifidobacteria (Bifidobacterium longum, B. breve and B. infantis) and Streptococcus salivarius subsp. thermophilus…
Randomised, double-blind, placebo-controlled studies have shown VSL#3 is effective in preventing the onset of acute pouchitis in patients with newly formed surgical pouches, and in maintaining remission following antibacterial treatment of acute pouchitis in patients with a history of refractory or recurrent pouchitis.
Treatment guidelines from the US and the UK include VSL#3 as a therapeutic option for the prevention of pouchitis relapse in patients with chronic pouchitis. In general, VSL#3 was well tolerated in clinical trials. Large, well designed, controlled confirmatory clinical trials will further determine the place of VSL#3 in the treatment of ulcerative colitis…”